Featured Articles

AbbVie and Gilgamesh Pharmaceuticals announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will…
Read More...

As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology…
Read More...

Kite, a Gilead Company and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the…
Read More...

Novartis announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing…
Read More...

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's…
Read More...

Bayer and the German-based life science company, Evotec, announced that they have updated the focus of their strategic collaboration to developing innovative precision treatments for…
Read More...

Merck, a leading science and technology company, is investing more than € 300 million in a new research center at its global headquarters in Darmstadt, Germany. In the Advanced Research…
Read More...

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of…
Read More...

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated…
Read More...

Evotec SE and Variant Bio, Inc. announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Fibrosis is characterised by marked and…
Read More...

Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher…
Read More...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+)…
Read More...

Bristol Myers Squibb and 2seventy bio, Inc. have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel; ide-cel) for the…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with…
Read More...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced it has signed an agreement to acquire the Genentech large-scale biologics…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and…
Read More...

Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved SPEVIGO (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP)…
Read More...

Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains…
Read More...